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Abstract: Recently, microRNAs (miRNAs) in circulating extracellular vesicles (EVs), have emerged
as a source of potential biomarkers for various pathophysiological conditions, including metabolic
disorders such as diabetes. Type 2 diabetes mellitus (T2DM), is the most prevalent form of diabetes in
the USA, with 30 million diagnosed patients. Identifying miRNA biomarkers that can be used to
assess response to glucose lowering treatments would be useful. Using patient plasma samples from a
subset of the Danish Metagenomics of the Human Intestinal Tract (MetaHIT) cohort, we characterized
miRNAs from whole plasma, plasma-derived EVs, and EV-depleted plasma by small RNA-sequencing
to identify T2DM associated miRNAs. We identified several miRNAs that exhibited concentration
changes between controls and non-metformin treated T2DM patients and we validated a subset of
these by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The results showed
that the concentrations of many T2DM-affected miRNAs in EV (but not in whole or EV-depleted
plasma) decreased to levels close to those of healthy controls following metformin treatment. Among
other potential uses of these differentially expressed miRNAs, some might be useful in assessing the
response to metformin in T2DM patients.
Keywords: microRNAs; extracellular vesicles; type 2 diabetes; metformin
1. Introduction
Diabetes is a major health epidemic accounting for a significant proportion of health-care-related
expenditures in many countries [1]. In the United States alone, there are about 30 million patients
living with diabetes, the majority with type 2 diabetes mellitus (T2DM) [2]. Elevated blood glucose is
the hallmark of T2DM, which eventually leads to micro- and macro-vascular complications of major
organs, among other effects. Onset of T2DM is usually preceded by a prediabetic phase, where blood
glucose levels are elevated but below the level for T2DM. In many cases prediabetes results from
development of insulin resistance (IR) of glucose metabolizing tissues which will eventually lead to
pancreatic β-cell dysfunction. Managing the blood glucose level through exercise, dietary change,
and drug treatment are the principal approaches to T2DM management. A drug to treat T2DM is
metformin, which primarily reduces hepatic gluconeogenesis thereby lowering tissue and circulating
levels of glucose [3].
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In recent years, cell-free microRNAs (miRNAs) present in various body fluids, including those
packaged in extracellular vesicles (EVs), have emerged as potential biomarkers for various diseases
and health conditions, including T2DM [3]. There have been several studies examining the changes
of circulating miRNAs associated with T2DM. One of the earliest studies identified several T2DM
affected circulating miRNAs, and found the plasma miR-126-5p level is changed in both T2DM
patients and mouse models [4]. Other studies have also observed the association of miR-126-5p level
in plasma with insulin treatment [5–7]. Additional T2DM associated circulating miRNAs, such as
miR-30d-5p [6–8], miR-122-5p [9–11], miR-146a-5p [8,12], miR-192-5p [13,14], and miR-375-5p [7,8] have
also been reported. Several of these miRNAs, such as miR-30d-5p [9], miR-122-5p [9], miR-126-5p [5],
and miR-192-5p [15] have also been associated with prediabetes. While these circulating miRNAs
show promise for identifying individuals with T2DM, the results of our meta-analysis showed many
inconsistent findings among studies, which may have been caused by differences in sample preparation
methods or miRNA measurement platforms [16]. All miRNA measurement platforms have advantages
and disadvantages. For example, next generation sequencing (NGS) based small-RNA sequencing
(sRNAseq) provides higher dynamic range and allows for the analysis of all potential miRNAs, and
even identification of novel miRNAs, when compared to quantitative reverse transcription-polymerase
chain reaction (qRT-PCR), or microarray making it a better method for discovery-based studies. On the
other hand, sRNAseq protocols, particularly the commercial library construction kits, are prone to
severe sequence-specific biases. To address this, a modified small RNA sequencing library construction
method, as well as a comprehensive data analysis pipeline, that allows for significant improvement of
miRNA analysis from biological samples were developed [17,18]. This improved approach has been
used in several diabetes related studies, including the identification of circulating miRNAs associated
with the progression of T2DM from prediabetic individuals [19,20].
Many circulating miRNA studies do not consider EVs in circulation as a separate sample type
rather using whole biofluids, such as plasma and serum. Those few EV based studies often use
isolation methods such as ultracentrifugation or precipitation, which may alter their properties
and co-purify RNAs associated with RNA-binding proteins or lipoproteins [21,22]. There are some
technical advancements to improve the reproducibility of circulating miRNA studies in recent years.
These including a size exclusion chromatography (SEC) based EV purification, an improved small
RNA library construction method [18], and better tools to align short RNA sequence reads [17]. In the
current study, we analyzed the small RNA spectra from whole plasma, plasma EVs and EV-depleted
plasma obtained from T2DM patients (with or without metformin treatment) and from healthy control
individuals who participated in the Danish part of the Metagenomics of the Human Intestinal Tract
(MetaHIT) study [23].
Several circulating miRNAs including some EV-encapsulated miRNAs that are associated with
T2DM or affected by metformin treatment were identified. These miRNAs may serve as possible
biomarkers, assessing metformin treatment response in patients with T2DM.
2. Materials and Methods
2.1. Sample and Study Collection
Fasting plasma samples were obtained from a subset of the Danish MetaHIT cohort [23]. In the
present study we included 80 individuals: 39 controls, 10 T2DM (non-metformin treated), and 31 T2DM
(treated with metformin). Samples were matched for age, and body mass index (BMI) (Supplemental
Table S1). Anthropometrics and biochemical measurements were obtained as previously described [24].
Plasma glucose was analyzed by a glucose oxidase method (Granutest, Merck, Darmstadt, Germany).
HbA1c was measured on TOSOH G7 by ion-exchange high performance liquid chromatography. Serum
insulin (excluding des-31,32-proinsulin and intact proinsulin) was measured using the AutoDELFIA
insulin kit (Perkin-Elmer, Wallac, Turku, Finland). HOMA-IR was calculated as: (fasting plasma
glucose (mmol/L) × fasting serum insulin (mU/L))/22.514. BMI was calculated as weight (kg) divided
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by height (m2) and obesity defined as BMI > 30 kg/m2. Plasma samples were collected after an
overnight fast into EDTA-treated tubes and spun at 1000× g at 4 ◦C for 10 min to remove blood cells,
and then 2000× g at 4 ◦C for 15 min to remove platelets and stored at −80 ◦C. Before RNA isolation, the
plasma samples were spun at 10,000× g at 4 ◦C for 10 min to remove any remaining cellular debris and
platelets. Prior to EV and RNA isolation, the plasma samples were spun at 10,000× g at 4 ◦C for 10 min
to remove platelets and cellular debris.
2.2. Isolation of EV and EV-Depleted Fractions
EVs were isolated from 200 µL of plasma using size-exclusion chromatography (SEC) (qEV column,
Izon Science, Cambridge, MA, USA) with de-gassed PBS as previously described [25]. Briefly, eluate
fractions (∼500 µL each fraction) containing EVs (fractions 7–10) were collected and the subsequent
fractions (11–35) were also collected as EV-depleted fractions. To confirm the purification of EVs
from samples, the SEC-purified EVs were quantified using the qNano particle counter (Izon Science,
Cambridge, MA, USA) using a NP150 pore, and visualized with transmission electron microscopy as
previously described [21].
2.3. RNA Isolation and Small RNA Sequencing Library Construction
Circulating RNA was isolated from whole plasma, EVs, and EV-depleted fractions using the
miRNeasy kit according to the manufacturer’s instructions. The RNA was eluted in 14 µL nuclease-free
H2O, and the quantity and quality were assessed using a Bioanalyzer pico chip (Agilent Technologies,
Santa Clara, CA, USA). To analyze circulating miRNA, we used a modified small-RNA library
construction protocol to reduce small RNA library construction associated bias [18]. Individual library
concentrations were assessed by NEBNext Library Quant Kit for Illumina (New England Biolabs,
Ipswich MA), pooled (2 nM final concentration) and then run on a NextSeq500 sequencer (Illumina,
San Diego, CA, USA).
2.4. Data Analysis
Sequence files (FASTQ format) were processed with an in-house small RNA analysis
pipeline—sRNAnalyzer [17]. Briefly, the adapters were trimmed from the sequence reads, low
complexity, low quality, and short reads (less than 15 nucleotides) were removed. The processed reads
(reads that passed filtering) were then mapped against miRBase (www.mirbase.org) v21. The mapping
was performed with single assignment and zero mis-matches allowed. The miRNA mapping results
were normalized using read count per million of processed read and then log2 transformed. Based on
the results, several invariant miRNAs (miRNAs that had a low sample to sample coefficient of
variance across all samples, including plasma, EVs, and EV-depleted plasma) were identified, including
miR-451a-5p and miR-486-5p. To be considered for analysis, a given miRNA had to have greater
than 10 reads in at least 50% of samples, across all samples, including plasma, EVs, and EV-depleted
plasma. To be considered to have a significant concentration change, a miRNA required a fold change
greater than 1.5 (or a log2 fold change > ±0.60) with a p-value < 0.05 (calculated using the Wilcoxon
rank sum test and corrected for multiple hypothesis testing using Benjamini-Hochberg). The miRTar
database (mirtar.mbc.nctu.edu.tw/ ) was used to identify miRNA-mRNA interaction targets to determine
biological processes that may be regulated by specific miRNA. In this approach, we required that each
miRNA target must be validated by at least two different experimental methods. Gene enrichment
analysis was performed with DAVID (Database for Annotation, Visualization and Integrated Discovery,
https://david.ncifcrf.gov/), using default settings. Enrichment was based on the Benjamini-Hochberg
corrected p-values for KEGG terms.
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2.5. qRT-PCR
Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) validation of miRNAs
was performed using TaqMan Advanced miRNA assays (Thermo Fisher, Waltham, MA, USA).
MiR-451a-5p and miR-486-5p were used as normalizers, since they were identified as invariant
miRNAs in the sample set (low coefficient of variance across samples) based on the miRNA mapping
results. Relative miRNA values are presented by ∆∆Ct values (Ct reference − Ct target) [26].
2.6. Ethics
The study was approved by the Ethical Committees of the Capital Region of Denmark
(HC-2008-017 and H-15000306) and was in accordance with the principles of the Declaration of
Helsinki. All individuals gave written informed consent before participating in the study.
3. Results
3.1. Isolation of EVs from Fasting Plasma Samples of Healthy Controls and T2DM
From the 80 individuals in the discovery set, 39 were healthy controls, 10 were non-metformin
treated T2DM, and 31 were metformin-treated T2DM patients (Supplemental Table S1). The samples
were matched with respect to gender, age and BMI, and showed no significant differences between the
groups (Supplemental Table S1). To explore the possible changes in circulating miRNA profiles among
the groups, we used next generation sequencing (NGS) platform to characterize the miRNA spectra
in whole plasma, EVs, and EV-depleted plasma for each patient. EVs isolated from plasma had an
average size of 122 nm, with an estimated average concentration of 4.24 × 108 EVs/mL (Figure 1A).
Electron microscopy images of EVs from these samples showed the presence of vesicles of ~100 nm in
diameter with typical morphology (Figure 1B,C). The EVs, along with whole plasma and EV-depleted
plasma, were then used to isolate RNA for small RNA analysis (Figure 1D–L).
3.2. MiRNA Levels from Small RNA Sequencing
About 10 million reads on average across all samples were obtained, among them approximately
7 million reads passed the pre-processing step (removal of adapter sequences and short or low
complexity reads) (Table 1). In plasma, about 1.1 million processed reads mapped to various human
miRNAs, while on average 293,000 and 634,000 reads mapped to various miRNAs in EV and EV-depleted
samples, respectively (Table 1). In whole plasma, EVs, and EV-depleted plasma on average 693, 423,
and 617 different miRNAs were observed (with at least one mapped read) in each sample, respectively.
Among these observed miRNAs in whole plasma, EVs, and EV-depleted plasma, 446, 242, and 352
miRNAs had 10 or more mapped reads, respectively (Table 1).
J. Clin. Med. 2019, 8, 617 5 of 17
J. Clin. Med. 2019, 8, x FOR PEER REVIEW 4 of 17 
2.6. Ethics 
The study was approved by the Ethical Committees of the Capital Region of Denmark (HC-2008-
017 and H-15000306) and was in accordance with the principles of the Declaration of Helsinki. All 
individuals gave written informed consent before participating in the study. 
3. Results 
3.1. Isolation of EVs from Fasting Plasma Samples of Healthy Controls and T2DM 
From the 80 individuals in the discovery set, 39 were healthy controls, 10 were non-metformin 
treated T2DM, and 31 were metformin-treated T2DM patients (Supplemental Table S1). The samples 
were matched with respect to gender, age and BMI, and showed no significant differences between 
the groups (Supplemental Table S1). To explore the possible changes in circulating miRNA profiles 
among the groups, we used next generation sequencing (NGS) platform to characterize the miRNA 
spectra in whole plasma, EVs, and EV-depleted plasma for each patient. EVs isolated from plasma 
had an average size of 122 nm, with an estimated average concentration of 4.24 × 108 EVs/mL (Figure 
1A). Electron microscopy images of EVs from these samples showed the presence of vesicles of ~100 
nm in diameter with typical morphology (Figure 1B,C). The EVs, along with whole plasma and EV-
depleted plasma, were then used to isolate RNA for small RNA analysis (Figure 1D–L). 
 
Figure 1. Isolation and characterization of extracellular vesicles (EVs) and RNA from plasma. (A) 
Histogram of EV isolated from plasma (B,C) EV imaged using TEM (D–J) bioanalyzer traces from 
whole plasma, EV, and EV-depleted (EVD) samples. (A) Histogram generated by qNano particle 
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Figure 1. Isolation and characterization of extracellular vesicles (EVs) and RNA from plasma.
(A) Histogram of EV isolated from plasma (B,C) EV imaged using TEM (D–J) bioanalyzer traces
from whole plasma, EV, and EV-depleted (EVD) samples. (A) Histogram generated by qNano particle
tracker of EVs isolated using SEC from patient plasm samples, with n average particle size of
122 nm. (B) Electron micrographs taken fr m isolated EVs, showing particles of a similar size that
have characteristic shape and form of EVs. Black bar represents 200 nm scale. (C) E largement of
boxed in area in (B). Black bar represents 100 nm scale. (D–L) Agilent RNA bioanalyzer traces of RNA
isolated from control plasma (D), control EVs (E), control EVD (F), non-metformin (non-met) treated
T2DM plasma (G), non-metformin treated type 2 diabetes mellitus (T2DM) EVs (H), non-metformin
treated T2DM EVD (I), metformin (met) treated T2DM plasma (J), metformin treated T2DM EVs (K),
and metformin treated T2DM EVD (L).
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Table 1. Overview of sequencing results.
Fraction Whole Plasma EV EV-Depleted Plasma (EVD)
Sample Control
T2DM
(Non-Metformin
Treated)
T2DM
(Metformin
Treated)
Average Control
T2DM
(Non-Metformin
Treated)
T2DM
(Metformin
Treated)
Average Control
T2DM
(Non-Metformin
Treated)
T2DM
(Metformin
Treated)
Average
Raw reads 9,883,520 11,530,667 10,712,888 10,709,025 9,724,030 10,252,856 9,146,014 9,707,634 10,102,865 9,629,667 10,027,784 9,920,105
Processed reads 7,103,119 7,633,060 7,373,665 7,369,948 6,747,232 6,856,590 6,254,425 6,619,416 7,911,233 7,404,532 7,579,322 7,631,695
Reads mapped to miRNA 1,156,073 1,215,783 1,166,777 1,179,544 224,714 372,528 284,460 293,901 535,018 779,273 590,431 634,907
Observed (>1 mapped) 685 706 688 693 420 445 404 423 585 642 624 617
Detected miRNAs (>10 reads) 423 472 445 446 231 273 222 242 323 383 351 352
Overview of small-RNA sequencing (sRNAseq) results, per group including for each fraction isolated. Raw reads are unfiltered reads, processed reads are after filtering for none-informative
reads, reads mapped to microRNAs (miRNAs) are based on single assignment with no mismatches, Observed miRNA are miRNAs with at least one mapped read.
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3.3. miRNAs Associated with T2DM
The miRNA spectra between control and non-metformin treated T2DM patients were analyzed
to identify miRNAs associated with T2DM. Using > ±0.6 log2 fold change (~1.5 fold concentration
change) and p-value < 0.05 as cut-off, 44 dysregulated miRNAs in whole plasma, 62 in EVs, and 108 in
EV-depleted plasma were identified where the majority of them showing increased concentrations
in T2DM patients (Figure 2A–C, Supplemental Table S2). Sixty eight percent of the T2DM affected
miRNAs (30/44) overlap between whole plasma and EV-depleted plasma (Figure 2D). Based on the
assay availability, concentration in sample, and prior reported association with T2DM, 9 miRNAs that
were dysregulated in whole plasma and EV-depleted plasma (miR-99a-5p, miR-122-5p, miR-130a-3p,
miR-136-3p, miR-146a-5p, miR-192-5p, miR-339-5p, miR-483-3p, miR-885-5p) and 5 dysregulated in
EVs (miR-23a-3p, miR-26a-5p, miR-126-3p, miR-139-5p, miR-203a-3p) were selected for qRT-PCR
verification. We were able to verify the concentration changes from 11 out of 14 selected miRNAs (7/9
from whole plasma, 8/9 from EV-depleted plasma, and 4/5 in EVs) (Figure 3A–C).
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Figure 2. miRNAs with concentration changes between T2DM patients and healthy controls.
(A–C) volcano plots for non-metformin (non-met) treated T2DM versus controls. (E–G) volcano
plots for metformin (met) treated T2DM versus controls. (I–K) volcano plots for metformin treated
versus non-metformin treated T2DM. Volcano plots showing miRNA log2 fold change (log2FC) versus
p-value between non-metformin treated T2DM and control samples in plasma (A), EVs (B), EV-depleted
(EVD) fractions (C), and (D) overlap between miRNAs that show concentration differences in plasma,
EVs, and EVD fractions. Volcano plots showing miRNA log2 fold change (log2FC) versus p-value
between treated T2DM and control in plasma (E), EVs (F), EVD fractions (G), and (H) overlap between
miRNAs that show concentration differences in plasma, EVs, and EVD fractions. Volcano plots showing
miRNA log2 fold change (log2FC) versus p-value between metformin treated T2DM and non-metformin
treated T2DM in plasma (I), EVs (J), EVD fractions (K), and (L) overlap between miRNAs that show
concentration differences in plasma, EVs, and EVD fractions. Grey unfilled circles represent miRNAs
with a p-value >0.05, and red circles represent miRNAs with a p-value < 0.05, and a log2FC > ±0.60
(fold change greater than 1.5).
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Figure 3. qRT-PCR validation of sRNAseq results in plasma, EVs, and EV-depleted (EVD) plasma.
Log2FC for plasma (A), EVs (B) and EVD (C). qRT-PCR validation of sRNAseq data for selected
miRNAs in plasma (A), EVs (B), and EVD fractions (C). Results are shown as ∆∆Ct values (max cycles
− (Ct reference − Ct target). MiR-451a and miR-486-5p were used as standards. Statistically significant
results are designated by asterisks (* p < 0.05, ** p < 0.01). Results with p > 0.05 are greyed-out.
Corresponding sRNAseq results are shown below as either purple bars (elevated in plasma/EVD) or
yellow bars (elevated in EVs).
3.4. miRNAs Affected by Metformin Treatment
When comparing controls and T2DM patients treated with metformin, 9 dysregulated miRNAs in
whole plasma, 9 in EVs, and 78 in EV-depleted plasma showed concentration changes (Figure 2E–G,
Supplemental Table S2). Eight out of 9 dysregulated miRNAs in whole plasma also showed
concentration changes in EV-depleted plasma (Figure 2H). Compared to the miRNA identified
between control and non-metformin treated T2DM patients, several affected miRNAs are in common;
however, their concentration changes were smaller in metformin-treated T2DM patient samples
(Supplemental Table S2) in whole plasma (Figure 4A), EVs (Figure 4B), and EV-depleted plasma
(Figure 4C).
In addition to healthy controls, we also compared the miRNA profiles in whole plasma, EVs,
and EV-depleted plasma between T2DM patients with or without metformin treatment. Most of the
affected are from EV-encapsulated miRNA, with 42 miRNAs showed concentration differences with
metformin treatment and only 2 affected miRNAs in whole plasma and none in EV-depleted plasma
(Figure 2I–K). Of the 42 dysregulated miRNAs in EVs, all of them showed decreased concentrations
in T2DM patients treated with metformin compared to their non-treated counterparts, (Figure 2B,J).
Furthermore, many of these miRNAs also showed significant concentration changes between controls
and non-metformin treated T2DM patients (Supplemental Table S2). More of the miRNAs are elevated
in non-metformin treated T2DM patients, whereas metformin-treated T2DM patients have values
comparable to healthy control subjects, specifically in the EV (Figure 5A), but not in the corresponding
EV depleted plasma (Figure 5B).
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Figure 4. Selected miRNAs with concentration changes between controls and non-metformin (non-met)
treated, and metformin-treated (met treated) T2DM. Plots of selected miRNAs showing concertation
differences between controls, non-metformin treated T2DM and metformin treated T2DM patients in
plasma, EV and EV-depleted samples. Plasma miRNA plots (A) are depicted in blue, EV miRNA plots
(B) are depicted in red, and EV-depleted miRNA plots (C) are depicted in green. The values are in log2
RPM (log2 transformed reads per million), with each dot representing a patient sample. The invariant
miRNAs, miR-451a-5p and miR-485-5p, are also shown. Statistically significant results are designated
by asterisks (* p < 0.05, ** p < 0.01), and non-significant results are designated as ‘NS’.
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Figure 5. EV-specific miRNAs that reflect changes both associated with T2DM and treatment
with metformin. Plots of selected miRNAs showing concertation differences between controls,
non-metformin (non-met) treated T2DM and metformin (met) treated T2DM patients in EV and
EV-depleted (EVD) plasma samples. EV miRNA plots (A) are depicted in red, and EV-depleted plasma
miRNA plots (B) are depicted in green. The values are in log2 RPM (log2 transformed reads per
million), with each dot representing a patient sample. Statistically significant results are designated by
asterisks (* p < 0.05, ** p < 0.01), and non-significant results are designated as ‘NS’.
3.5. Prediction of Potential Biological Pathways Associated with miRNAs
We sought to identify biological processes and pathways that may be affected by miRNAs
associated with T2DM in whole plasma, EVs, and EV-depleted plasma. We used the miRNAs that
showed concentration changes between T2DM patients without metformin treatment and controls
(Figure 2D), metformin-treated T2DM patients and controls (Figure 2H) in their respective sample
types. We identified experimentally validated mRNA targets of these miRNAs using the miRTar
database [27] and used the DAVID online tool [28] to identify potentially enriched biological pathways
(based on KEGG terms) associated with T2DM-affected miRNAs. These pathways include regulation
of homeostasis, metabolism, and uptake of glucose; signaling through insulin receptor; the TGFβ/BMP
signaling pathway; the Notch signaling pathway; and regulation of the inflammatory response
(Figure 6A,B). Many of these pathways were shared among whole plasma, EVs, and EV-depleted
plasma, but some showed higher enrichment in EVs, such as inflammatory, insulin signaling, and
glucose-related pathways.
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3.6. Comparison of Plasma miRNAs Between Prediabetes, T2DM, and T2DM Treated with Metformin
We previously used the same method to analyze plasma miRNA differences in a cohort of
prediabetic individuals (METSIM study) where some progressed to T2DM and some remained
at prediabetic to identify predictive marker for the onset of T2DM [20]. While the cohorts are
different some of the perturbed miRNAs in plasma overlap between METSIM (the METSIM samples
were at prediabetic baseline prior to T2DM progression) and MetaHIT cohorts. For example, the
concentrations of miR-99a-5p, miR-122-5p, miR-192-5p, miR-193a-5p, miR-193b-5p, and miR-483-5p all
were significantly changed in both between progressors and non-progressors in METSIM, and between
T2DM patients (without metformin treatment) and controls in MetaHIT (Figure 7A–F). The biological
processes enriched for miRNAs identified in METSIM data were also perturbed in T2DM patients in
MetaHIT cohort. As with miRNA concentration changes, the enrichment of these pathways returns to
near pe-diabetic (METSIM) levels in metformin-treated T2DM patients (Supplemental Figure S1).
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(T2DM treated with metformin). (A) miR-122-5p, (B) miR-192-5p, (C) miR-193b-3p, (D) miR-193a-5p,
(E) miR-483-5p, (F) miR-99a-5p. Plots of selected plasma miRNAs that overlap between METSIM and
MetaHIT datasets. The levels of miRNAs from MetaHIT data are shown as dark grey dots, while the
miRNA levels from the METSIM data (Ghai et al. 2019a) are shown as light grey dots. The values are
in log2 RPM (log2 transformed reads per million), with each dot representing a patient sample.
4. Discussion
Circulating miRNAs may show promise as diagnostic and prognostic biomarkers for various
diseases and pathologies including T2DM; however, additional studies are needed to identify and
validate candidate miRNAs of clinical relevance. To understand the impact of T2DM and metformin
treatment on circulating miRNA, we characterized the miRNAs in whole plasma, EVs, and EV-depleted
plasma, all from subjects in the fasting state. The EV-depleted plasma contains RNA associated with
RNA binding proteins such as AGO2, NPM1 [29,30] and lipoproteins—HDL and LDL complexes [25].
Since vesicle encapsulated and protein complexed RNAs arise from very different processes and may
have different biological implications, analyzing the small RNA content in both EV and EV-depleted
plasma gives us a richer view, in principle, of the biological status of the subjects.
In this study we identified 162 circulating miRNAs affected by T2DM in whole plasma, plasma
EVs, and EV-depleted plasma. The majority of the affected miRNAs are present in whole plasma as
well as EV-depleted plasma, while many T2DM-affected miRNAs in EVs were unique, suggesting
EV miRNA are processed by a different mechanism than EV-depleted plasma. This observation
emphasizes the usefulness of separating EV and EV-depleted biofluid in circulating RNA studies.
Using qRT-PCR the concentrations changes of several of these T2DM affected miRNAs were verified.
The consistency between qRT-PCR and sRNAseq results suggests that the improved EV isolation, small
RNA sequencing library construction method and RNA mapping strategy provide more accurate small
RNA profiles.
Many of the T2DM affected miRNAs we identified (e.g., miR-122-5p, miR-192-5p, miR-193b-5p,
miR-146a-5p in plasma/EV depleted plasma; and miR-26a-5p, miR-126-5p, and miR-144-3p in EVs) have
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previously been shown to be dysregulated in T2DM patient plasma/serum samples (Supplementary
Figure S2) [9,13,16,31]; however, this study also identified a number of new T2DM affected miRNAs,
including, several T2DM affected miRNAs that were observed previously only in animal models or
tissue culture (miR-136-3p, miR-382-5p, miR-495-3p in plasma [16,32] and miR-203a-3p, miR-424-5p in
EVs) [33,34]. We also observed that several of these miRNAs that have been previously observed to be
associated with prediabetes and T2DM (miR-122-5p, miR-192-5p, miR-193b-5p [9,13,15]) show similar
concertation differences between our METSIM and MetaHIT samples sets. The higher concentration
differences of these miRNAs in the MetaHIT cohort likely associated with the difference in dysregulated
metabolic processes between prediabetes and T2DM. It is interesting that after been treated with
metformin the levels of these miRNAs return to similar levels seen in the prediabetic individuals in the
METSIM cohort (Figure 7A–F).
Due to the complex heterogenous nature of plasma and other biofluids, the exact cellular/tissue
sources of these circulating miRNAs (both vesicles and non-vesicle encapsulated) are somewhat
speculative. However, there are some evidences that some of these miRNAs are enriched in tissues
that are associated with T2DM. For example, miR-122-5p has been shown to be expressed highly in the
liver [35], and miR-126-5p, miR-146a-5p, and miR-375-3p have been shown to have some enrichment
in cells of the pancreas [7]. This suggests that some of the dysregulated circulating miRNAs in T2DM
may be derived from these tissues, however additional experiments are required to validate this.
In addition to the effect of T2DM, the impact of metformin treatment on the spectra of circulating
miRNA was also examined. While there was no significant difference in FPG/HbA1c levels between
T2DM patients in this study with or without metformin treatment, the metformin-treated T2DM
patients had significantly higher circulating insulin and C-peptide levels than both non-treated T2DM
patients and healthy controls (Supplementary Table S1) suggesting that these T2DM patients had
a more severe form of insulin resistant T2DM. In addition, we observed that patients treated with
metformin have a spectrum of circulating miRNA more similar to healthy controls in both plasma and
EVs. This suggests that the metformin treatment has a “beneficial” effect based on the restoration of the
circulating miRNA spectrum, though the mechanism for this effect is entirely unclear. When compared
to miRNA levels in non-treated T2DM patients, the levels of some EV-encapsulated miRNAs were
decreased in metformin-treated patients, suggesting a reduction in some miRNA cargo in response
to metformin. For example, the concentrations of several miRNAs including let-7b-5p, miR-15a-5p,
miR-15b-5p, miR-16-5p, miR-16-2-3p, miR-25-3p, miR-30b-5p, miR-106b-3p, miR-195-5p, miR-3613-5p,
and miR-424-5p were increased in T2DM but decreased to the normal range after metformin treatment
(Figure 5A). Unlike the miRNAs discussed above, there is little current evidence of these circulating
miRNAs being involved in T2DM, aside from miR-15a-5p which has been associated with prediabetic
progression to T2DM [31].
Based on the validated gene targets of T2DM affected miRNAs in whole plasma, EVs, and
EV-depleted plasma, we observed enrichment of biological pathways that are potentially associated
with T2DM pathophysiology, including those related to glucose homeostasis, insulin secretion, and
the TGFβ/BMP and Notch signaling pathways (Figure 8). While these pathways are predicted to be
enriched (compared to controls) in non-metformin treated T2DM patients, they are not associated with
patients treated with metformin. While intriguing, further studies are clearly needed to determine if
these changes of biological pathways potentials relate to metformin-treatment associated changes of
biochemical and physiological variables.
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